Testing effectiveness (Phase 2)Study completedNCT06033261
What this trial is testing
MRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
Who this might be right for
Genital Herpes
ModernaTX, Inc. 365